

Health-related Quality of Life and Long-term Outcomes after Mildly Symptomatic COVID-19: Exploring the Protocol

Lucas Borges Pereira,^{1,2} João Paulo Vilela Rodrigues,¹ Fabiana Rossi Varallo,¹ Leonardo Régis Leira Pereira¹

Faculdade de Ciências Farmacêuticas de Ribeirão Preto, Universidade de São Paulo,¹ Ribeirão Preto, SP - Brazil

Faculdade de Ciências da Saúde de Barretos Dr. Paulo Prata,² Barretos, SP - Brazil

Short Editorial related to the article: Health-Related Quality of Life and Long-Term Outcomes after Mildly Symptomatic COVID-19: The Post-COVID Brazil Study 2 Protocol

The post-COVID-19 condition has been defined by the World Health Organization as a “condition that occurs in individuals with a history of probable or confirmed SARS-CoV-2 infection, typically after three months from the onset of COVID-19, with symptoms lasting at least two months and that an alternative diagnosis can not explain.” The primary symptoms associated with this condition include fatigue, muscle and joint pain, shortness of breath, sleep difficulties, mental and neurological symptoms such as depression and anxiety, loss of smell and taste, headache, and difficulty in thinking and concentrating.^{1,2} The cytopathic effect of the virus on the endothelium, along with endothelial damage as a consequence of systemic inflammation, has been associated with cardiovascular events such as myocarditis, myocardial infarction, arrhythmias, and thromboembolic events.³

Various studies conducted worldwide have also found evidence of other signs and symptoms.⁴⁻⁷ However, the incidence of these symptoms has shown significant variation due to the heterogeneity of the studies. This variation may be associated with factors such as the post-COVID study period, the region where the study was conducted, and the severity of the disease.⁴

It is estimated that by 2021, 3.92 billion people had been infected with the SARS-CoV-2 virus, and 3.7% had developed the post-COVID-19 condition.¹ Due to the high number of people who have already been infected at least once and the limited evidence regarding the consequences this disease can have on patients, prospective studies in individuals infected with SARS-CoV-2 can contribute to a better understanding of this condition, especially in the long term.

The manuscript “Health-related quality of life and long-term outcomes after mildly symptomatic COVID-19: The post-COVID Brazil study protocol” aims to evaluate factors associated with patients’ quality of life one year after mild SARS-CoV-2 infection

in Brazil. The authors also propose to study the periods of 3, 6, and 9 months after infection.⁸

Brazil is a country that provides an excellent field of study for this health issue, as it has one of the highest incidences of COVID-19 in the world.⁹ Brazilian studies have covered regionalized samples¹⁰⁻¹³ and longitudinal studies with a short period observation or cross-sectional designs.^{11,14} Rover et al. intend to analyze the Brazilian population in addition to the one-year study period.⁸ However, centers from the Northeast region will not be included, and only one center from the Central-West and one from the North regions will be included, thus posing a limitation to the study. It is worth noting that the highest incidence of COVID-19 in Brazil occurs in the South and Central-West regions.⁹

Another strength of this study is the amount of information that will be collected to understand the manifestations of post-COVID-19 conditions. Quality of life, mortality, complications, symptoms, functional status, demographic data, comorbidities, vaccination status, and laboratory tests will be obtained for this assessment. Much information will be obtained through telephone interviews, an appropriate strategy for a multi-center study. However, the authors did not report an estimated duration of the interview, and it is known that long interviews carry a higher risk of collecting erroneous data due to interviewee and interviewer fatigue.

Despite the limitations, we believe the study is relevant since the published works on post-COVID-19 conditions have mainly focused on the progression of patients with a history of moderate to severe infection. Therefore, data on the long-term outcomes of patients who had mild disease that included individuals from different Brazilian regions are scarce. Furthermore, this study’s results will enhance healthcare professionals’ work in caring for patients infected with SARS-CoV-2.

Keywords

COVID-19; SARS CoV-2; Inflammation/complications; Myocarditis; Myocardial Infarction; arrhythmias Cardiac; Thromboembolism.

Mailing Address: Lucas Borges Pereira •

FACISB - Av. Loja Maçônica Renovadora 68, nº 100. Postal Code 14785-002, Bairro Aeroporto, Barretos, SP – Brazil

E-mail: lucasborgespereira82@gmail.com

Manuscript received September 11, 2023, revised manuscript September 13, 2023, accepted September 13, 2023

DOI: <https://doi.org/10.36660/abc.20230639>

References

1. World Health Organization. Post COVID-19 condition. Available in: <https://www.who.int/teams/health-care-readiness/post-covid-19-condition>. Access in: aug 2023.
2. World Health Organization. Clinical management of COVID-19. Available in: <https://www.who.int/publications/i/item/WHO-2019-nCoV-clinical-2023.2>. Access in: aug 2023.
3. Santoro L, Zaccone V, Falsetti L, Ruggieri V, Danese M, Mio C, et al. Role of Endothelium in Cardiovascular Sequelae of Long COVID. *Biomedicines*. 2023;11(8):2239. doi: 10.3390/biomedicines11082239
4. Alkodaymi MS, Omrani OA, Fawzy NA, Shaar BA, Almamlouk R, Riaz M, et al. Prevalence of post-acute COVID-19 syndrome symptoms at diferente follow-up periods: a systematic review and meta-analysis. *Clin Microbiol Infect*. 2022;28(5):657-66. doi: 10.1016/j.cmi.2022.01.014
5. Ceban F, Ling S, Lui LM, Lee Y, Gill H, Teopiz KM, et al. Fatigue and cognitive impairment in Post-COVID-19 Syndrome: A systematic review and meta-analysis. *Brain Behav Immun*. 2022;101(1):93-135. doi: 10.1016/j.bbi.2021.12.020
6. Premraj L, Kannapadi NV, Briggs J, Seal SM, Battaglini D, Fanning J, et al. Mid and long-term neurological and neuropsychiatric manifestations of post-COVID-19 syndrome: A meta-analysis. *J Neurol Sci*. 2022;434(1):120162. doi: 10.1016/j.jns.2022.120162
7. Elbeltagi R, Al-Beltagi M, Saeed NK, Bediwy AS. COVID-19-induced gastrointestinal autonomic dysfunction: A systematic review. *World J Clin Cases*. 2023;11(22):5252-72. doi: 10.12998/wjcc.v11.i22.5252
8. Marciane Maria Rover, Geraldine Trott, Fernando Luís Scolari, Mariana Motta Dias da Silva, Denise de Souza, Rosa da Rosa Minho dos Santos, et al. Health-Related Quality of Life and Long-Term Outcomes after Mildly Symptomatic COVID-19: The Post-COVID Brazil Study 2 Protocol. *Arq Bras Cardiol*. 2023; 120(9):e2023-0639. DOI: <https://doi.org/10.36660/abc.20230639>
9. BRASIL. Ministério da Saúde. Painel Coronavírus. Available in: <https://covid.saude.gov.br/>. Access in: sep 2023.
10. Silva NS, Araújo NK, dos Santos KA, Souza KS, Araújo JN, Cruz MS, et al. Post-Covid condition and clinic characteristics associated with SARS-CoV-2 infection: a 2-year follow-up to Brazilian cases. *Sci Rep*. 2023;13(1):13973. doi: 10.1038/s41598-023-40586-8
11. Barreto AP, Barreto Filho MA, Duarte LC, Cerqueira-Silva T, Camelier A, Tavares NM, et al. Metabolic disorders and post-acute hospitalization in black/mixed-race patients with long COVID in Brazil: A cross-sectional analysis. *PLoS One*. 2022;17(10):e0276771. doi: 10.1371/journal.pone.0276771
12. Lapa J, Rosa D, Mendes JP, Deusdará R, Romero GA. Prevalence and Associated Factors of Post-COVID-19 Syndrome in a Brazilian Cohort after 3 and 6 Months of Hospital Discharge. *Int J Environ Res Public Health*. 2023;20(1):848. doi: 10.3390/ijerph20010848
13. Miranda DA, Gomes SV, Filgueiras PS, Corsini CA, Almeida NB, Silva RA, et al. Long COVID-19 syndrome: a 14-months longitudinal study during the two first epidemic peaks in Shoutheast Brazil. *Trans R Soc Trop Med Hyg*. 2022;116(11):1007-14. doi: 10.1093/trstmh/trac030
14. Talhari C, Criado PR, Castro CC, Ianhez M, Ramos PM, Miot HÁ. Prevalence of and risk factors for post-COVID: Results from a survey of 6,958 patients from Brazil. *Na Acad Bras Cienc*. 2023;95(1): e20220143. doi: 10.1590/0001-3765202320220143

